2015 First Quarter Earnings Call

April 30, 2015

Forward-Looking Statements

2

Some of the statements made in this presentation whether written or

oral may be “forward-looking statements” within the meaning of Section

27A of the Securities Act of 1933, as amended, and Section 21E of the

Securities Exchange Act of 1934, as amended, and involve a number of

risks and uncertainties. These statements can be identified by

terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,”

“plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential”, or

“continue”, or variations or the negative of these terms or other

comparable terminology.

These statements are based on the company’s current expectations.

The company’s actual results could differ materially from those stated or

implied in such forward-looking statements. The company assumes no

obligations to update forward-looking information, including information

in this presentation, to reflect changed assumptions, the occurrence of

unanticipated events or changes in future operating results, financial

conditions, prospects or otherwise.

Earnings Call Participants

Thomas J. Hook

President & CEO

Michael Dinkins

Executive Vice President & CFO

Betsy Cowell

Vice President Finance & Treasurer

3

Agenda

Thomas J. Hook

Executive Summary

First Quarter 2015 Performance

Michael Dinkins

Balance Sheet Review

2015 Guidance Update

Thomas J. Hook

Neurostimulation Update

Question & Answer

4

Executive Summary

We are confirming our guidance for the total year

Our Neurostimulation strategy is showing success

Algostim subsidiary proposed spin-off will enhance the

strategic flexibility and focus of each business

Orthopaedics continues sustainable double digit growth

Portable Medical fell short again this quarter – transition of

production is on schedule and we have a strong pipeline of

projects

Energy impacted by market weakness

Margin expansion initiatives are on or ahead of schedule

5

Selected Q1 2015 Highlights

6 * Greatbatch organic constant currency growth rate: -7%; Orthopaedics organic constant currency growth rate:18% ** See appendix for GAAP reconciliation except for ROIC (TTM) 6

(Amounts in millions except for EPS) Q1 Q1 Variance

Sales* $161.3 $174.3 -7%

Adjusted:**

Operating Income $17.2 $22.3 -23%

EBITDA $26.4 $31.6 -16%

ROIC (TTM) 7.7% 8.0% -30 BPS

Operating Cash flow $7.3 $7.0 5%

Diluted EPS $0.54 $0.54 0%

Adj.

EPS

Comments

2014 Q1 Adjusted EPS $ 0.54

Volume/Mix (0.13) Lower volumes and unfavorable mix partially

offset by acquisition of CCC Medical Devices

Taxes 0.11 Tax rate

Other 0.02 FX gains partially offset by higher share count

2015 Q1 Adjusted EPS $0.54

Q1 2015 Revenue

7

Q1 2015 Q1 2014 % Organic

Actual Actual Change CC Growth

Greatbatch Medical

CN $76,273 $86,780 -12% -12%

Orthopaedics 38,971 36,431 7% 18%

Portable Medical 13,667 19,203 -29% -29%

Vascular 10,356 13,050 -21% -21%

Energy & Other 17,710 18,131 -2% -2%

Total Greatbatch Medical 156,977 173,595 -10% -7%

QiG 5,047 686 636% 71%

Elimination of Intersegment Sales* -704 NA

Total Sales $161,320 $174,281 -7% -7%

*Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and

neuromodulation product line.

Cardiac/Neuromodulation

Battery

Feedthrough

Enclosure

Q1 revenue up 11% on sequential quarter basis

Batteries and shield assemblies continue to deliver strong

growth

Current quarter customer launches partially offset by

customer order patterns

Negative $5M impact from end of life products

Coated

Electrode

Q1 R4Q

Revenue $75,569* $310,208

% of Total Revenue 47% 46%

Growth -12% -9%

8

Greatbatch Sustainable Advantages

Strong and expanding customer relationships

90% of the portfolio secured by long term agreements

Sustainable and growing patent portfolio

Innovative product offerings (+20 programs)

*Net of intersegment sales (reported CN Sales total $76,273)

Orthopaedics

18% organic constant currency growth

Strong implant franchise…~6% YTD growth despite FX

headwinds

Double digit growth continues in instruments

Winning with our bone cutting preparation technology and

the service model we employ in delivery systems Reamer

Delivery System

Implant

Q1 R4Q

Revenue $38,971 $149,836

% of Total Revenue 24% 22%

Growth 7% 9%

9

Greatbatch Sustainable Advantages

Strong and expanding customer relationships

70% secured by long term agreements

Continued strong market acceptance in bone cutting and

preparation technologies

Portable Medical

Integrated Power

Supplies

Battery Packs

Amounts in millions

Q1 R4Q

Revenue $13,667 $63,507

% of Total Revenue 8% 9%

Growth -29% -20%

Executing the shift to higher value technologies

Building pipeline with new technology in power solutions

Leveraging our global footprint to improve overall competitiveness

10

Greatbatch Sustainable Advantages

Focus on innovative proprietary powers solutions

Wireless charging and power

Miniaturization … Batteries and power cells

Value added assembly capabilities

New Product Introductions – 23 active projects

Vascular

Customer inventory management and timing of new product

introductions

Focus on high growth sectors Complex, steerable catheter shafts for Electrophysiology market

Catheter shafts for peripheral and neuro vascular markets

Delivering value to customers…product moves on track

Introducer

Steerable Sheath

Amounts in millions

Amounts in millions

Q1 R4Q

Revenue $10,356 $56,076

% of Total Revenue 6% 8%

Growth -21% 10%

11

Greatbatch Sustainable Advantages

Expanding customer relationships with 50% secured by long-

term agreements

Specialized manufacturing know-how

Leveraging global manufacturing foot print

Innovative product offerings

EME

Amounts in millions

Q1 R4Q

Revenue $17,710 $81,336

% of Total Revenue 11% 12%

Growth -2% 4%

Demand stable… Customers focused on battery power/technology

to enable more efficiency in exploration and production activities

Winning with battery technology…wide range and high

temperature

12

Greatbatch Sustainable Advantages

Industry leading quality and reliability … 40+ years

experience with critical applications Extensive battery chemistry knowledge/fundamentals

including proprietary electrolytes

Ability to leverage a diversified, enterprise wide, knowledge

base

State-of-the-art production facilities

Battery Packs

Battery Cells

Battery Chargers

Balance Sheet & ROIC

13

Balance Sheet Metrics

($ in millions except for EPS)

14

Q1 2015 Q1 2014 FY2014

Days Sales Outstanding 62 61 66

Days Inventory Outstanding 115 92 103

Leverage Ratio <1.5 <1.5 <1.5

Our balance sheet is solid and our capital structure yields a leverage ratio well below 1.5

Trailing 12 months Q1 2015 Q1 2014

Adjusted EBITDA $123.3 $122.4

ROIC 7.7% 8.0%

Q1 2015 Q1 2014

Working Capital $249 $215

Operating Cash Flow $7.3 $7.0

2015 Guidance

15

2015 Guidance – Confirming Guidance

16

(In millions, except for EPS amounts)

2014

2015 Guidance

Sales $687.8 $715 - $730

Adjusted Operating Margin 13.3% 13.7% - 14.0%

Adjusted Diluted EPS $2.42 $2.61 - $2.71

Operating Cash Flows $81.3 $80 - $100

Capex $24.8 $40 - $50

ROIC 8.4% 9.0%

Neurostimulation Update

17

18

Neurostimulation Market Overview

Total Neurostimulation Market

Spinal Cord

Stimulators

Deep Brain

Stimulators

Vagus Nerve

Stimulators

Sacral Nerve

Stimulators

Market Segmentation: The Neurostimulation market is segmented by the type of nerve targeted:

Spinal Cord Stimulators (SCS): Pain management devices that act like a pacemaker to deliver

electrical signals to the spinal cord to treat chronic pain.

Deep Brain Stimulators (DBS): Systems specifically designed to deliver electrical impulses to

either inhibit or stimulate specific nerve signals, thereby offering relief for certain neurological

disorders.

Vagus Nerve Stimulators (VNS): An adjunctive treatment with leads implanted around the vagal

nerve in the neck to address the unmet needs of patients suffering with epilepsy and treatment-

resistant depression.

Sacral Nerve Stimulators (SNS): These systems are designed to deliver low-amplitude electrical

stimulation to the sacral nerve roots that help treat fecal incontinence, urinary urge, urinary

frequency, and urinary retention.

Source: Frost & Sullivan analysis.

19

Neurostimulation Market Opportunity (US)

Equity investments

Research

Prototyping

Component

manufacturing for

clinical trials

GB Ventures

Leads

Batteries

Feed throughs

FDA Experience

Quality Systems

Platform system reduces

time and risk to market

Other Neurostimulation

indications

Early stage innovation Medical device components Medical device systems

Positioned to Win Significant Neurostimulation Market Share

20

Considering the Spin-off of our Algostim Subsidiary

21

Enhances the strategic flexibility and focus of each business

– Better allocation of resources to meet the needs of the respective businesses

– Ability to pursue distinct capital allocation strategies

– Focused on different growth opportunities and provides a clearer investment proposition to attract long term investors best suited to each company

Capitalizes on Greatbatch’s intellectual property portfolio holdings and supports Greatbatch position to retain and grow its global manufacturing foot print

– Leverages Greatbatch’s design, development and manufacturing capabilities in its served markets

– Harnesses the combined intellectual property standing with its customers and engineering services of CCC Medical Devices and NeuroNexus

Expands and creates new Greatbatch customers

Appendix

22

Q1 2015 Financial Results

23

Three Months Ended

(Dollars in thousands, except per share data)

April 3, April 4, %

2015 2014 Change

Sales $ 161,320 $ 174,281 (7 )%

Organic Constant Currency Sales Growth (7 )% 17 %

GAAP Operating Income $ 9,389 $ 22,524 (58 )%

GAAP Operating Income as % of Sales 5.8 % 12.9 %

Adjusted Operating Income* $ 17,244 $ 22,310 (23 )%

Adjusted Operating Income as % of Sales 10.7 % 12.8 %

GAAP Diluted EPS $ 0.31 $ 0.58 (47 )%

Adjusted Diluted EPS* $ 0.54 $ 0.54 — %

Adjusted EBITDA* $ 26,422 $ 31,562 (16 )%

Adjusted EBITDA as a % Sales 16.4 % 18.1 %

Q1 2015 Operating Cash Flow

($ in millions)

Net income $8.0

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depreciation and Amortization 9.2

Debt related Amortization included on Int Expense 0.2

Stock Based Compensation/Discount Amortization 2.3

Other non-cash Gains (1.1)

Deferred Income Taxes (0.6)

Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable 14.3

Inventories (8.7)

Prepaid expenses and other current assets 1.0

Accounts payable (0.7)

Accrued expenses (12.6)

Income taxes payable (3.9)

Net cash provided by operating activities $7.3

24

GAAP Reconciliation

Operating Income Reconciliation – 3 Months

25

Three Months Ended

Greatbatch Medical QiG Unallocated Total

April 3, April 4, April 3, April 4, April 3, April 4, April 3, April 4,

(dollars in thousands) 2015 2014 2015 2014 2015 2014 2015 2014

Sales $ 156,977 $ 173,595 $ 5,047 $ 686 $ (704 ) $ — $ 161,320 $ 174,281

Operating income (loss) as

reported $ 21,753

$ 35,128

$ (5,450 ) $ (5,913 ) $ (6,914 ) $ (6,691 ) $ 9,389

$ 22,524

Adjustments: Consolidation and

optimization (income)

expenses 6,771

(927 ) 157

27

—

685

6,928

(215 )

Acquisition and integration

(income) expenses —

—

44

(430 ) 22 2

66

(428 )

Asset dispositions,

severance and other 116

428

232

—

513 1

861

429

Adjusted operating

income (loss) $ 28,640

$ 34,629

$ (5,017 ) $ (6,316 ) $ (6,379 ) $ (6,003 ) $ 17,244

$ 22,310

Adjusted operating

margin 18.2 % 19.9 % N/A N/A N/A N/A 10.7 % 12.8 %

Net Income and Diluted EPS Reconciliation

GAAP Reconciliation

a) Net of tax amounts computed using a 35% U.S., Mexico, and France statutory tax rate, a 25% Uruguay statutory tax rate and a 0% tax rate for Swiss adjustments.

b) Pre-tax amount is a gain of $0.5 million and $0.8 million for the 2015 and 2014 periods, respectively.

c) The Federal R&D tax credit has not yet been extended for 2015. The 2014 Federal R&D tax credit was enacted in the fourth quarter of 2014. Amounts assume

that the tax credit was effective at the beginning of the year for 2015 and 2014.

d) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.

26

Three Months Ended

April 3, 2015

April 4, 2014

(in thousands except per share amounts) Net

Income

Per Diluted Share

Net Income

Per Diluted Share

Net income as reported $ 8,008 $ 0.31

$ 14,922 $ 0.58

Adjustments:

Consolidation and optimization (income) expenses(a) 5,387 0.21

(964 ) (0.04 )

Acquisition and integration (income) expenses(a) 46 —

(278 ) (0.01 )

Asset dispositions, severance and other(a) 585 0.02

279 0.01

(Gain) loss on cost and equity method investments, net(a)(b) (324 ) (0.01 ) (534 ) (0.02 )

R&D Tax Credit(c) 400 0.02

400 0.02

Adjusted net income and diluted EPS(d) $ 14,102 $ 0.54

$ 13,825 $ 0.54

Adjusted diluted weighted average shares 26,219 25,694

Adjusted EBITDA reconciliation

GAAP Reconciliation

27

Three Months Ended

April 3, April 4,

(dollars in thousands) 2015 2014

Sales $ 161,320 $ 174,281

Adjusted operating income* $ 17,244 $ 22,310

Add: Depreciation and amortization 9,178 9,252

Adjusted EBITDA $ 26,422 $ 31,562

Adjusted EBITDA as a % of sales 16.4 % 18.1 %

Betsy Cowell Vice President Finance & Treasurer Greatbatch 2595 Dallas Parkway Suite 310 Frisco, Texas 75034 214 618 4982 ecowell@greatbatch.com www.greatbatch.com

Contact Information

28